Supplementary figure 1: Histogram representing the rate of partial control and resistance of first generation SSA according to the choice of different second line treatments (m-Peg-V, c-Peg-V and Pasireotide Lar), taking in account data of the sub-analysis for cases treated with Pasireotide Lar for at least 6 months. Univariate analysis.

Supplementary figure 2: Histogram representing the efficacy of Pasireotide Lar at 6 months of treatment, according to the response to first-gen SSA. Univariate analysis.